Growth in iron deficiency injectable market is driven by rising PCOS prevalence

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Iron Deficiency Injectable Market During The Forecast Period?

The iron deficiency injectable market size has demonstrated significant expansion in recent years. It is projected to increase from $15.22 billion in 2025 to $16.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.0%. This historical growth can be attributed to the high prevalence of iron deficiency anemia, the limited efficacy of oral iron therapies, a rise in chronic kidney disease cases, the growth in hospital-based infusion treatments, and wider clinical acceptance of injectable iron.

The iron deficiency injectable market is projected to experience substantial growth in the coming years, reaching $25.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.3%. This expansion during the forecast period is driven by factors such as an increasing geriatric population, rising prevalence of cancer and IBD, the spread of homecare infusion services, enhanced safety profiles of newer formulations, and expanding healthcare access in emerging markets. Significant trends anticipated during this period include a growing preference for injectable iron over oral therapies, increased application in chronic kidney disease management, the development of day-care and short-duration infusion protocols, the proliferation of generic injectable iron products, and greater adoption in oncology and chronic disease treatment.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp

What Primary Drivers Are Shaping The Iron Deficiency Injectable Market?

The increasing occurrence of polycystic ovary syndrome (PCOS) is projected to fuel the expansion of the iron deficiency injectables market in the future. PCOS is recognized as a prevalent hormonal disorder impacting individuals with ovaries, primarily women in their reproductive years. PCOS can lead to various issues, including iron overload, and notably contributes to excessive blood loss during menstruation. This blood loss often renders patients anemic, a condition that injectable iron deficiency medications can address. As an illustration, data from June 2023, provided by the World Health Organization, a US-based specialized health agency, indicates that globally, approximately 8–13% of reproductive-aged women are affected by PCOS, with 70% of these cases going undiagnosed. Consequently, the widespread nature of polycystic ovary syndrome (PCOS) is a primary driver for the growth of the iron deficiency injectables market.

How Is The Iron Deficiency Injectable Market Organized By Segment Classification?

The iron deficiency injectable market covered in this report is segmented –

1) By Type: Iron Dextran, Ferric Carboxymaltose

2) By Branded or Generics: Branded, Generics

3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Ferric Carboxymaltose: Injectafer, Ferinject

What Trends Are Affecting The Growth Of The Iron Deficiency Injectable Market?

Key companies in the iron deficiency injectables market are developing new treatments, such as INJECTAFER, to maintain their market presence. For example, in June 2023, Daiichi Sankyo Company, a US-based healthcare provider, and American Regent Inc., a US-based injectables manufacturer, launched INJECTAFER (ferric carboxymaltose injection) for iron deficiency, which received approval from the Food And Drug Administration, a US-based government agency. This product represents the first and only intravenous iron replacement therapy approved by the FDA for adult patients suffering from chronic and progressive heart failure. INJECTAFER’s performance was assessed through more than 40 clinical trials involving over 8,800 participants from various countries. This recent approval further validates INJECTAFER’s successful and demonstrated application in these patient populations, including adult and pediatric patients with iron-deficient anemia and heart failure.

Who Are The Industry Participants Involved In The Iron Deficiency Injectable Market?

Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Fresenius Medical Care, AbbVie Inc., Bayer AG, AstraZeneca Plc, GSK Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc.

Get The Full Iron Deficiency Injectable Market Report:

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Which Geographic Region Dominates The Iron Deficiency Injectable Market?

North America was the largest region in the iron deficiency injectable market in 2025. The regions covered in the iron deficiency injectable market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Iron Deficiency Injectable Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Browse Through More Reports Similar to the Global Iron Deficiency Injectable Market 2026, By The Business Research Company

Hemochromatosis Iron Overload Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Direct Reduced Iron Market Report

https://www.thebusinessresearchcompany.com/report/direct-reduced-iron-global-market-report

Foundries Market Report

https://www.thebusinessresearchcompany.com/report/foundries-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795